Recombinant Human ProDynorphin protein

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

ProDynorphin also known as PDYN or preproenkephalin B serves as a precursor protein for the dynorphins. Dynorphins are class of opioid peptides that the body uses for modulating pain response and tailored hormone release. ProDynorphin appears with a mass of around 25 kDa and is expressed widely in the brain including areas such as the hippocampus and hypothalamus. Localization in the pituitary gland also occurs where it significantly contributes to the regulation of neuroendocrine systems.

Biological function summary

This protein influences a variety of physiological processes. Neurons express ProDynorphin in abundant amounts reflecting its importance in neurotransmission where it acts through specific receptors like the kappa opioid receptor. ProDynorphin is not known to function as part of a larger multiprotein complex but its role in signal pathways clearly impacts pain perception emotional response and addiction mechanisms in the central nervous system by releasing dynorphin A peptides among others.

Pathways

Researchers link ProDynorphin to significant opioid receptor pathways and stress response mechanisms. The protein interacts with key molecules such as the kappa opioid receptor influencing the opioid receptor signaling pathway. Another pathway influenced by ProDynorphin involves the dopamine system which connects it through shared roles with the peptide proenkephalin leading to potential impacts on reward and mood regulations due to dopamine's activity in these contexts.

ProDynorphin holds significance in conditions like chronic pain and mood disorders. Dysregulation or mutation in the gene encoding this protein associates with altered pain sensitivity and susceptibility to depressive disorders. Its direct connection to the kappa opioid receptor further ties it to addiction-related disorders as kappa receptor signaling commonly impacts withdrawal and relapse behaviors. The study of ProDynorphin within these diseases offers potential therapeutic targets for managing pain and mood dysregulation.